{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:16:22Z","timestamp":1775081782649,"version":"3.50.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T00:00:00Z","timestamp":1678838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Chikungunya fever (CHIKF) has spread to more than 100 countries worldwide, with frequent outbreaks in Europe and the Americas in recent years. Despite the relatively low lethality of infection, patients can suffer from long-term sequelae. Until now, no available vaccines have been approved for use; however, increasing attention is being paid to the development of vaccines against chikungunya virus (CHIKV), and the World Health Organization has included vaccine development in the initial blueprint deliverables. Here, we developed an mRNA vaccine using the nucleotide sequence encoding structural proteins of CHIKV. And immunogenicity was evaluated by neutralization assay, Enzyme-linked immunospot assay and Intracellular cytokine staining. The results showed that the encoded proteins elicited high levels of neutralizing antibody titers and T cell-mediated cellular immune responses in mice. Moreover, compared with the wild-type vaccine, the codon-optimized vaccine elicited robust CD8<jats:sup>+<\/jats:sup> T-cell responses and mild neutralizing antibody titers. In addition, higher levels of neutralizing antibody titers and T-cell immune responses were obtained using a homologous booster mRNA vaccine regimen of three different homologous or heterologous booster immunization strategies. Thus, this study provides assessment data to develop vaccine candidates and explore the effectiveness of the prime-boost approach.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1129118","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T06:47:36Z","timestamp":1678862856000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Construction and immunogenicity of an mRNA vaccine against chikungunya virus"],"prefix":"10.3389","volume":"14","author":[{"given":"Jingjing","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xishan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingxing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enyue","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minglei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zelun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60281-X","article-title":"Chikungunya: a re-emerging virus","volume":"379","author":"Burt","year":"2012","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/v14050969","article-title":"A review on chikungunya virus epidemiology, pathogenesis and current vaccine development","volume":"14","author":"de Lima Cavalcanti","year":"2022","journal-title":"Viruses"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmaid.2021.102168","article-title":"Chikungunya and arthritis: An overview","volume":"44","author":"Kumar","year":"2021","journal-title":"Travel Med Infect Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02449-17","article-title":"Chikungunya virus strains show lineage-specific variations in virulence and cross-protective ability in murine and nonhuman primate models","volume":"9","author":"Langsjoen","year":"2018","journal-title":"mBio"},{"key":"B5","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.107.3.643","article-title":"Production and evaluation of a formalin-killed chikungunya vaccine","volume":"107","author":"Harrison","year":"1971","journal-title":"J Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.02.062","article-title":"Assessment of immunogenic potential of vero adapted formalin inactivated vaccine derived from novel ECSA genotype of chikungunya virus","volume":"27","author":"Tiwari","year":"2009","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30238-3","article-title":"Single-shot live-attenuated chikungunya vaccine in healthy adults: A phase 1, randomised controlled trial","volume":"20","author":"Wressnigg","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.1038\/s41467-021-24906-y","article-title":"A single dose of ChAdOx1 chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial","volume":"12","author":"Folegatti","year":"2021","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32488-7","article-title":"Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial","volume":"392","author":"Reisinger","year":"2019","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00226-2","article-title":"Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: A randomised, double-blind, parallel-group, phase 2 trial","volume":"22","author":"Bennett","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.virs.2022.01.032","article-title":"An mRNA vaccine encoding chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses","volume":"37","author":"Ge","year":"2022","journal-title":"Virol Sin"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203315","article-title":"Evaluation of mRNA-1273 covid-19 vaccine in children 6 to 11 years of age","volume":"386","author":"Creech","year":"2022","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200674","article-title":"Safety and efficacy of a third dose of BNT162b2 covid-19 vaccine","volume":"386","author":"Moreira","year":"2022","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy639","article-title":"Safety and immunogenicity of a heterologous prime-boost Ebola virus vaccine regimen in healthy adults in the united kingdom and Senegal","volume":"219","author":"Venkatraman","year":"2019","journal-title":"J Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/v2020435","article-title":"Heterologous prime-boost HIV-1 vaccination regimens in pre-clinical and clinical trials","volume":"2","author":"Brown","year":"2010","journal-title":"Viruses"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131571","article-title":"Ad35.CS.01-RTS,S\/AS01 heterologous prime boost vaccine efficacy against sporozoite challenge in healthy malaria-na\u00efve adults","volume":"10","author":"Ockenhouse","year":"2015","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.531","article-title":"Revival of the heterologous prime-boost technique in COVID-19: An outlook from the history of outbreaks","volume":"5","author":"Siddiqui","year":"2022","journal-title":"Health Sci Rep"},{"key":"B21","doi-asserted-by":"publisher","first-page":"E322","DOI":"10.3390\/v11040322","article-title":"Assessment of immunogenicity and neutralisation efficacy of viral-vectored vaccines against chikungunya virus","volume":"11","author":"L\u00f3pez-Camacho","year":"2019","journal-title":"Viruses"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.10.007","article-title":"Development and application of a bioluminescent imaging mouse model for chikungunya virus based on pseudovirus system","volume":"35","author":"Wu","year":"2017","journal-title":"Vaccine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3201\/eid1210.060610","article-title":"Novel chikungunya virus variant in travelers returning from Indian ocean islands","volume":"12","author":"Parola","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A thermostable mRNA vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2020.1743767","article-title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2","volume":"9","author":"Nie","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0040180","article-title":"High guanine and cytosine content increases mRNA levels in mammalian cells","volume":"4","author":"Kudla","year":"2006","journal-title":"PLoS Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00280-9","article-title":"Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: A randomised, double-blind, placebo-controlled, phase 1 trial","volume":"3","author":"Chen","year":"2022","journal-title":"Lancet Microbe"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03453-13","article-title":"Novel attenuated chikungunya vaccine candidates elicit protective immunity in C57BL\/6 mice","volume":"88","author":"Halleng\u00e4rd","year":"2014","journal-title":"J Virol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300304","article-title":"An essential role of antibodies in the control of chikungunya virus infection","volume":"190","author":"Lum","year":"2013","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"E231","DOI":"10.3390\/pathogens8040231","article-title":"A single and un-adjuvanted dose of a chimpanzee adenovirus-vectored vaccine against chikungunya virus fully protects mice from lethal disease","volume":"8","author":"Campos","year":"2019","journal-title":"Pathogens"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq006","article-title":"The acute phase of chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation","volume":"204","author":"Wauquier","year":"2011","journal-title":"J Infect Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1202177","article-title":"A pathogenic role for CD4+ T cells during chikungunya virus infection in mice","volume":"190","author":"Teo","year":"2013","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1355245","article-title":"Mechanism of action of mRNA-based vaccines","volume":"16","author":"Iavarone","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrm.2017.91","article-title":"Codon optimality, bias and usage in translation and mRNA decay","volume":"19","author":"Hanson","year":"2018","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2012.06.010","article-title":"Silent substitutions predictably alter translation elongation rates and protein folding efficiencies","volume":"422","author":"Spencer","year":"2012","journal-title":"J Mol Biol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring mRNA vaccine to balance Innate\/Adaptive immune response","volume":"26","author":"Linares-Fern\u00e1ndez","year":"2020","journal-title":"Trends Mol Med"},{"key":"B38","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41392-021-00843-6","article-title":"Heterologous prime-boost with AdC68- and mRNA-based COVID-19 vaccines elicit potent immune responses in mice","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2021.1902245","article-title":"Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates","volume":"10","author":"He","year":"2021","journal-title":"Emerging Microbes Infections"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2003.09.001","article-title":"Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells","volume":"283","author":"Karlsson","year":"2003","journal-title":"J Immunol Methods"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2005.07.014","article-title":"Monitoring of cellular responses after vaccination against tetanus toxoid: Comparison of the measurement of IFN-\u03b3 production by ELISA, ELISPOT, flow cytometry and real-time PCR","volume":"305","author":"Tassignon","year":"2005","journal-title":"J Immunol Methods"},{"key":"B43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0022-1759(01)00416-1","article-title":"Use of overlapping peptide mixtures as antigens for cytokine flow cytometry","volume":"255","author":"Maecker","year":"2001","journal-title":"J Immunol Methods"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.612747","article-title":"Optimize Prime\/Boost vaccine strategies: Trained immunity as a new player in the game","volume":"12","author":"Palgen","year":"2021","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1590\/s0100-879x2012007500142","article-title":"Recombinant vaccines and the development of new vaccine strategies","volume":"45","author":"Nascimento","year":"2012","journal-title":"Braz J Med Biol Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1129118\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T06:47:40Z","timestamp":1678862860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1129118\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,15]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2023.1129118"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1129118","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,15]]},"article-number":"1129118"}}